Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157 patients with advanced cancers who progressed on systemic therapy were tested for 21 mutations in BRAF, EGFR, KRAS, and PIK3CA using the BEAMing...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2015
Subjects:
Clinical Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494976/
https://ncbi.nlm.nih.gov/pubmed/25980577
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items